NCT01462214 - Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Metastatic Renal Cell Cancer

Interventions

DRUG

Everolimus

Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.

Trial Locations (13)

Unknown

Medisch Centrum Alkmaar, Alkmaar

NKI-AVL, Amsterdam

Universitair Medisch Centrum Groningen, Groningen

Spaarne Ziekenhuis Hoofddorp, Hoofddorp

Medisch Centrum Leeuwarden, Leeuwarden

University Hospital Maastricht, Maastricht

St. Antonius Ziekenhuis, Nieuwegein

UMC St Radboud Nijmegen, Nijmegen

Sint Franciscus Gasthuis Rotterdam, Rotterdam

Haga Ziekenhuis, The Hague

Medisch Centrum Haaglanden, The Hague

Isala Klinieken Zwolle, Zwolle

1081 HV

VU University Medical Center, Amsterdam